Real world patterns of dyslipidemia care before and after a national fee revision in Japan: A nationwide study using a 30 million patient claims database Authors: Satoshi Yamasaki, Tomotake Tokunou, Takahiko Horiuchi, Jennifer Tucker, Yee Gary Ang, Yee Gary Ang, Yee Gary Ang Published: 2026 ABSTRACT Dyslipidemia is a key risk factor for cardiovascular disease, and its prevalence continues to rise with population aging in Japan. A 2024 change to the fee categories in Japan’s insurance system aimed to encourage a more holistic approach and better patient involvement in developing treatment plans; however, the real-world impact of these changes on patient outcomes remains unclear. Using a nationwide claims database, we sought to: (1) describe the achievement of low-density lipoprotein cholesterol goals and major adverse cardiovascular events among patients with dyslipidemia; (2) compare lipid control and outcomes under the previous disease-specific management fee with those under the new lifestyle disease management fee, and (3) identify patient groups that may benefit from additional lifestyle-based interventions. We conducted a retrospective cohort study among adults aged ≥ 18 years with dyslipidemia (International Classification of Diseases, Tenth Revision code E78) and at least one lipid measurement. In total, 590,000 patients contributed 23,600,010 outpatient visits. Ourpatient visits were the unit of observation for lipid and fee-category analyses; cardiovascular outcomes and patient-years were analyzed at the patient level. The primary outcome was low-density lipoprotein cholesterol goal attainment; secondary outcomes were changes in lipid parameters, major adverse cardiovascular events, and all-cause mortality. Low-density lipoprotein cholesterol goals were attained at 58.3% of outpatient visits under the previous fee and 58.5% under the new fee, and less often in secondary than in primary prevention, despite high statin use and frequent combination therapy with ezetimibe or fibrate. Lipid levels were broadly similar across fee periods. Cardiovascular event rates were also similar, but post-revision patient-years were limited to approximately 6 months (58,500 vs. 1,542,800 patient-years); therefore, this comparison is exploratory and cannot exclude an effect of the new fee structure. Longer follow-up and complementary designs are needed to evaluate the causal impact of the new fee on outcomes. Introduction Dyslipidemia is a major modifiable risk factor for cardiovascular disease, and its prevalence continues to increase in Japan, together with rapid population aging [1]. Despite the widespread use of lipid-lowering agents such as statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, real-world data from large administrative databases have consistently shown that a substantial proportion of high-risk patients fail to achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets [2]. Recent real-world observational data from cardiology outpatient clinics in Turkey similarly showed that many patients remain above target despite intensified statin-based therapy, and that adding ezetimibe improved but did not normalize goal attainment [3]. This residual risk highlights the limitations of pharmacotherapy alone and underscores the need for sustainable, lifestyle-based strategies that can be implemented as part of routine care. Complementary and non-pharmacological approaches, such as structured counseling on diet, physical activity, weight management, and smoking cessation, have attracted growing interest as adjuncts to conventional dyslipidemia management. These lifestyle-based strategies are increasingly embedded in chronic care programs and reimbursement schemes, including Japan’s new lifestyle disease management fee. The Japanese government has recognized the importance of addressing the social determinants of health in reducing and managing the risk of non-communicable diseases, such as cardiovascular disease, and has made changes to the medical reimbursement system to reflect this [4]. In Japan, most residents are covered by public insurance schemes, and patients generally pay a fixed copayment at the point of care. The remainder is reimbursed directly from insurers to medical facilities based on the national fee schedule. In 2024, the long-standing “specific disease management fee” for conditions such as hypertension, diabetes, and dyslipidemia was replaced by a new “lifestyle disease management fee,” which took effect on 1 June 2024 [5]. These “management fees” are paid to providers as add-on fees for ongoing, structured chronic disease management, rather than as direct payments to patients. The design of the management fee categories may therefore influence provider behavior, adoption, and adherence to chronic care programs. Eligibility for the lifestyle-related disease management fee, which is applicable to outpatient visits only and billed on a per-visit basis, requires physicians to work with patients to create and periodically review a structured Treatment Plan Sheet [5]. This covers both biomedical targets (e.g., LDL-C levels) and broader lifestyle and social determinants (e.g., sleep, physical activity, work conditions, body weight). This reform therefore comprised both a technical change in coding and a broader shift in the institutional framework for chronic disease care. The new management fee emphasizes comprehensive lifestyle management with integrated goals and includes lifestyle counseling, rather than the previous approach in which comorbidities were effectively treated in parallel with standard pharmacotherapy and brief, disease-focused counseling during routine outpatient visits. Pharmacotherapy remains guideline-based and disease-appropriate under the new system. The intended added value lies in the more holistic, goal-oriented, and lifestyle-focused management framework, rather than in changes to drug regimens [6]. Overall, the fee revision was designed to encourage a more comprehensive, collaborative approach, with patients and physicians working together to create and review treatment plans. In theory, this approach should enhance adherence and outcomes. However, as far as can be ascertained, no study to date has examined the effect of these changes on patient outcomes related to dyslipidemia. Therefore, questions remain, such as how often LDL-C goals are achieved in routine care, and whether there have been reductions in major adverse cardiac events. To address this gap, we conducted a nationwide retrospective cohort study using the Medical Data Vision (MDV) Diagnosis Procedure Combination (DPC) database, which includes approximately 30 million patients across acute care hospitals in Japan. We explored patterns of dyslipidemia care and outcomes before and after the 2024 fee revision to identify gaps in current care and potential target populations for future lifestyle-related interventions. Given the short post-revision observation window and observational design of the present study, our objective was not to estimate the causal effect of the fee revision but to provide an early descriptive snapshot of care patterns and outcomes surrounding implementation of the new lifestyle disease management fee. Methods Real-world data source We conducted a retrospective, observational study using the MDV (Medical Data Vision Co., Ltd., Tokyo, Japan) administrative claims and laboratory database, one of the largest hospital-based datasets in Japan. This database covers approximately 30 million patients from more than 450 acute care hospitals participating in the DPC system, including tertiary referral centers and large community hospitals. The MDV database excludes most small clinics and non-DPC facilities. It contains detailed information on demographics, diagnoses (International Classification of Diseases, Tenth Revision codes), procedures, prescriptions, hospitalizations, and laboratory test results. This broad coverage makes the MDV database well-suited for evaluating real-world treatment patterns and outcomes in patients with dyslipidemia. This database was accessed for research purposes on 15 October 2025. The authors had no access to any information that could directly identify individual participants at any time during or after data collection. Study design and population We identified adults (aged ≥ 18 years) with at least one International Classification of Diseases, Tenth Revision code for dyslipidemia (E78.x) and at least one recorded measurement of lipid parameters, total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), between 1 January 2021 and 31 December 2024. The index date (baseline) was defined as the earliest date on which both a dyslipidemia diagnosis and a lipid measurement were recorded during the study period. Inclusion criteria were: (1) age ≥ 18 years on the index date; (2) continuous observation in the database for at least 6 months after the index date; and (3) available baseline lipid data. We excluded patients with missing key demographic variables (age or sex) or incomplete baseline lipid data, as well as those with a follow-up duration of < 6 months. To reflect changes in the fee policy, we divided the observation period into two fee categories: (1) the specific disease management fee period (M1), from 1 January 2021–31 May 2024; and (2) the lifestyle disease management fee period (M2), from 1 June 2024–31 December 2024, during which time the new lifestyle disease management fee for hypertension, diabetes, and dyslipidemia was in place. Each patient was classified according to the predominant disease management fee category recorded during follow-up. In sensitivity analyses, we distinguished between patients who were treated for the first time under M2 and those who transitioned from M1 to M2. The primary unit of analysis for baseline characteristics was the patient; for the analyses of fee categories and visit-level outcomes, we used outpatient visits as the unit of observation. Individual patients could contribute multiple visits and could contribute visits to both fee categories, depending on the timing of their follow-up relative to the 2024 fee revision. Cohort subgroups Prespecified subgroups were defined according to: (1) age (< 65, 65–74, and ≥ 75 years); (2) cardiovascular risk category (primary prevention vs. secondary prevention after atherosclerotic cardiovascular disease, and the presence of diabetes mellitus or chronic kidney disease); and (3) baseline lipid levels. These strata were chosen to align with Japanese Atherosclerosis Society (JAS) guidelines [7] and to capture populations most likely to be considered for lifestyle-oriented or complementary interventions in future studies [8] Exposures and comparators The primary exposure was the disease management fee category (M1 vs. M2), reflecting the policy shift from disease-specific to lifestyle disease management for chronic cardiometabolic conditions. Pharmacological treatment patterns for dyslipidemia were also evaluated, including use of statins, ezetimibe, fibrates, PCSK9 inhibitors, and other lipid-lowering agents, alone or in combination. We compared lipid control and cardiovascular outcomes between the M1 and M2 periods overall and within age and risk subgroups, accounting for differences in drug regimens and comorbidities. Outcomes The primary outcome was the attainment of LDL-C goals, defined as achievement of JAS guideline targets based on cardiovascular risk: < 120 mg/dL in primary prevention and < 100 mg/dL (or < 70 mg/dL for very high-risk patients) in secondary prevention. Secondary lipid outcomes included absolute changes in TC, HDL-C, and TG from baseline to follow-up assessments. Clinical secondary outcomes included major adverse cardiovascular events (myocardial infarction, ischemic stroke, hospitalization for heart failure, and cardiovascular death), all-cause mortality, and hospitalization for any cardiovascular cause. We also assessed treatment persistence and adherence to lipid-lowering therapy, as reflected by prescription continuity in the claims data. For each disease management fee category, on-treatment lipid parameters (TC, LDL-C, HDL-C, and TG) were defined as the most recent lipid measurement obtained during the observation window while the patient was receiving lipid-lowering therapy. LDL-C goal attainment was assessed at this most recent on-treatment measurement under the predominant fee category (M1 or M2). For patients with health care visits during both fee periods, goal attainment was evaluated separately for each period using the relevant on-treatment measurements. Statistical analysis We used descriptive statistics to summarize patients’ baseline characteristics, disease management fee categories, and treatment patterns. We reported the mean with standard deviation or median with interquartile range for continuous variables and the frequency with percentage for categorical variables. For between-group comparisons (e.g., M1 vs. M2, age, and risk strata), we used chi-square tests for categorical variables and the Student t-test or analysis of variance for continuous variables. Additionally, we calculated standardized mean differences (SMDs) for baseline characteristics to assess the magnitude of between-group differences independent of the large sample size. An SMD with an absolute value < 0.1 was interpreted as indicating a negligible imbalance, consistent with common practice in observational studies. Cardiovascular outcomes and all-cause mortality were analyzed at the patient level rather than at the visit level. For each fee period, every patient who contributed at least one outpatient visit during that period was followed from the first qualifying visit until the event of interest, loss of database observation, or end of that fee period, whichever occurred first; crude incidence rates were then calculated per 1000 patient-years with exact (Poisson) 95% confidence intervals (CIs). Because a patient could contribute visits to both fee periods, and multiple visits within the same period, the M1 and M2 groups are not independent samples and visit-level proportions are clustered within patients. To avoid overstating precision, 95% CIs for visit-level proportions were calculated using the number of unique patients contributing visits in each stratum as the effective sample size, which is a deliberately conservative approach. Visit-level counts are reported as the number of outpatient visits and are never interpreted as the number of patients. All analyses were descriptive and exploratory; this study was not designed or powered to estimate causal effects of the fee revision. For all statistical analyses, we used EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [9], a graphical user interface for R that extends the functionality of R Commander, as well as R version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria). Ethical considerations The MDV database contains fully anonymized patient-level data collected for administrative and research purposes. In accordance with Japanese ethical guidelines for medical and health research involving human subjects, the use of anonymized secondary data in this study did not require individual informed consent. The study was approved by the Institutional Review Board of St. Mary’s Hospital, Kurume, Japan (approval number 25–0912). Results Study population and baseline characteristics From approximately 30 million patients in the MDV DPC database, we identified 590,000 adults with dyslipidemia who had at least one lipid measurement and at least 6 months of follow-up between 2021 and 2024 (Table 1). Most visits occurred in large acute care hospitals participating in the DPC system, including university hospitals and tertiary centers, with the remainder seen at non-university acute care hospitals. Among the 590,000 patients with dyslipidemia and at least 6 months of follow-up, approximately 472,000 (roughly 80%) had visits only under the specific disease management fee (M1), approximately 38,000 (roughly 6%) had visits only under the lifestyle disease management fee (M2), and approximately 79,000 (roughly 14%) had visits during both periods; this indicated that the M1 and M2 visit counts partially reflected the same patients over time. 10.1371/journal.pone.0358270.t001Table 1Baseline characteristics of the outpatient cohort with dyslipidemia, by management fee category (unit of observation: outpatient visits).VariableSpecific disease management fee period (M1)Lifestyle disease management fee period (M2) Total outpatient visits, n 21,000,0132,599,997 Unique patients contributing visits, n 551,000117,000 Age, years Mean ± SD67.4 ± 12.666.9 ± 12.8 Median (IQR)68 (59–76)67 (58–75) Age groups, n (%) < 65 years13,100,013 (62.4)1,719,997 (66.2) 65–74 years5,899,997 (28.1)639,999 (24.6) ≥ 75 years2,000,003 (9.5)240,001 (9.2) Men, n (%) 11,000,003 (52.4)1,399,999 (53.8) Comorbidities, n (%) Hypertension14,300,009 (68.1)1,699,993 (65.4) Diabetes mellitus8,199,997 (39.1)979,997 (37.7) Prior myocardial infarction2,599,993 (12.4)319,991 (12.3) Prior ischemic stroke1,899,997 (9.1)229,993 (8.8) Prior heart failure1,749,991 (8.3)209,989 (8.1) Cardiovascular risk category, n (%) Primary prevention14,499,991 (69.1)1,779,991 (68.5) Secondary prevention6,500,022 (31.1)820,006 (31.5) Baseline lipid parameters, mg/dL Total cholesterol Mean ± SD217.8 ± 38.2216.6 ± 38.6 Median (IQR)214 (191–241)213 (190–240) LDL-C Mean ± SD138.1 ± 32.4137.7 ± 32.8 Median (IQR)135 (115–158)134 (114–157) HDL-C Mean ± SD52.6 ± 14.152.4 ± 14.3 Median (IQR)51 (43–61)50 (42–60) Triglycerides Mean ± SD155.7 ± 89.1154.7 ± 89.6 Median (IQR)137 (97–191)136 (96–190) Current smoker, n (%) 4,299,997 (20.5)519,997 (20.1)Data are presented as n (%) for outpatient visits, unless otherwise specified; the unit of observation is the outpatient visit, and visit counts do not represent counts of distinct patients. The number of unique patients contributing visits in each fee period is shown separately.Standardized mean difference (M2 vs. M1) values were generally < 0.1, indicating a good balance in baseline characteristics between M1 and M2.IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SD, standard deviation. Baseline characteristics of the outpatient cohort with dyslipidemia, by management fee category (unit of observation: outpatient visits). Data are presented as n (%) for outpatient visits, unless otherwise specified; the unit of observation is the outpatient visit, and visit counts do not represent counts of distinct patients. The number of unique patients contributing visits in each fee period is shown separately. Standardized mean difference (M2 vs. M1) values were generally < 0.1, indicating a good balance in baseline characteristics between M1 and M2. IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SD, standard deviation. The outpatient cohort comprised 23,600,010 visit-level records, of which 21,000,013 visits were reimbursed under the specific disease management fee (M1) and 2,599,997 under the lifestyle disease management fee (M2). Accordingly, 551,000 unique patients (472,000 with M1 visits only plus 79,000 with visits in both periods) contributed the 21,000,013 M1 visits, and 117,000 unique patients (38,000 with M2 visits only plus 79,000 with visits in both periods) contributed the 2,599,997 M2 visits; the M1 and M2 visit counts therefore describe outpatient encounters, not distinct individuals. The mean patient age was similar across categories (67.4 years in M1 and 66.9 years in M2), with roughly one-third of visits involving patients aged 65–74 years and approximately 9%–10% involving those aged ≥ 75 years. Men accounted for just over half of visits in both groups (52.4% in M1 and 53.8% in M2). Although fewer patients contributed to M2 and its post-fee-revision observation window was shorter, the average number of outpatient visits per patient was higher in M2, resulting in a comparable total number of visits across the two fee categories over the study period. Each outpatient visit was treated as a separate observation, and individual patients could contribute multiple visits to either fee category depending on the timing of their follow-up relative to the 2024 fee revision. Comorbidities were common: hypertension was recorded in 68.1% of M1 visits and 65.4% of M2 visits and diabetes mellitus in 39.1% and 37.7%, respectively. Prior cardiovascular disease was also frequent, with 12.4% versus 12.3% of visits associated with previous myocardial infarction, 9.1% versus 8.8% with previous ischemic stroke, and 8.3% versus 8.1% with previous heart failure in M1 and M2. The distribution of cardiovascular risk categories was nearly identical between fee categories, with primary prevention accounting for 69.1% of M1 visits, 68.5% of M2 visits, and secondary prevention for 31.1% and 31.5%, respectively. Baseline lipid profiles were also highly comparable: mean TC was 217.8 mg/dL in M1 and 216.6 mg/dL in M2, mean LDL-C was 138.1 versus 137.7 mg/dL, mean HDL-C was 52.6 versus 52.4 mg/dL, and mean TG was 155.7 versus 154.7 mg/dL, with similar median and interquartile range values. Current smoking was reported in approximately one-fifth of visits (20.5% in M1 and 20.1% in M2). Across these variables, SMDs were generally below 0.1, indicating a good balance in baseline demographic, clinical, and lipid characteristics between M1 and M2, despite the large sample size. Pharmacological lipid-lowering therapy and on-treatment lipid levels During both study periods, most outpatient visits involved active pharmacological management of dyslipidemia (Table 2). Statins were prescribed in 81.9% of M1 visits and 82.3% of M2 visits; ezetimibe in 27.6% and 27.7%, respectively; fibrates in 11.9% of visits in both groups; and PCSK9 inhibitors in 2.5% of visits in each category. On-treatment lipid profiles were modestly improved as compared with baseline, but substantial residual dyslipidemia persisted. 10.1371/journal.pone.0358270.t002Table 2Lipid profile and treatment patterns by management fee category.ParameterSpecific disease management fee period (M1) (21,000,013 outpatient visits)Lifestyle disease management fee period (M2) (2,599,997 outpatient visits) Lipid-lowering therapy, n (%) Statin use17,199,997 (81.9)2,139,991 (82.3) Ezetimibe use5,799,991 (27.6)719,993 (27.7) Fibrate use2,499,997 (11.9)309,989 (11.9) PCSK9 inhibitor use519,991 (2.5)63,997 (2.5) Lipid parameters (on treatment), mg/dL Total cholesterol Mean ± SD195.5 ± 36.0194.9 ± 36.3 Median (IQR)191 (171–217)190 (170–216) LDL-C Mean ± SD114.8 ± 30.3114.3 ± 30.6 Median (IQR)111 (93–133)110 (92–132) HDL-C Mean ± SD54.8 ± 14.754.4 ± 14.9 Median (IQR)53 (45–63)52 (44–62) Triglycerides Mean ± SD141.8 ± 82.0140.9 ± 82.5 Median (IQR)125 (88–177)124 (87–176) LDL-C goal attainment a , n (%) Overall cohort12,249,996 (58.3)1,519,998 (58.5) Primary prevention group8,620,003 (59.4)1,069,999 (60.1) Secondary prevention group3,629,993 (55.8)449,999 (54.9)aLDL-C goals based on Japanese Atherosclerosis Society guidelines: < 120 mg/dL in primary prevention, < 100 mg/dL (or < 70 mg/dL for very high-risk) in secondary prevention.Data are shown as n (%) or mean ± SD.Values represent the most recent on-treatment lipid measurement within each patient’s observation period under the corresponding management fee category. Data are shown per outpatient visit as the unit of analysis because the lifestyle disease management fee is applicable only in the outpatient setting and on a per-visit basis.LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; PCSK9, proprotein convertase subtilisin/kexin type 9; SD, standard deviation. Lipid profile and treatment patterns by management fee category. aLDL-C goals based on Japanese Atherosclerosis Society guidelines: < 120 mg/dL in primary prevention, < 100 mg/dL (or < 70 mg/dL for very high-risk) in secondary prevention. Data are shown as n (%) or mean ± SD. Values represent the most recent on-treatment lipid measurement within each patient’s observation period under the corresponding management fee category. Data are shown per outpatient visit as the unit of analysis because the lifestyle disease management fee is applicable only in the outpatient setting and on a per-visit basis. LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; PCSK9, proprotein convertase subtilisin/kexin type 9; SD, standard deviation. Mean TC declined to 195.5 mg/dL in M1 and 194.9 mg/dL in M2, and mean LDL-C dropped to 114.8 mg/dL and 114.3 mg/dL, respectively. Mean HDL-C increased slightly to 54.8 mg/dL in M1 and 54.4 mg/dL in M2, whereas mean TG decreased to 141.8 mg/dL and 140.9 mg/dL, respectively. Differences in on-treatment lipid parameters between M1 and M2 were small and not clinically meaningful; SMDs were < 0.10 for all lipid variables, and no statistically significant differences were detected using t-tests or analysis of variance after adjustment for the large sample size. These findings suggest that the initial transition from specific disease management fee (M1) to lifestyle disease management fee (M2) did not substantially alter visit-level treatment intensity or on-treatment lipid levels within the observation window. LDL-C goal attainment overall and by prevention category Despite intensive pharmacotherapy at the visit level, guideline-recommended LDL-C goals based on JAS criteria were achieved in only approximately 60% of visits. Overall, LDL-C targets were attained in 58.3% of M1 visits and 58.5% of M2 visits. The difference between M1 and M2 was statistically negligible (chi-square test, p < 0.05; SMDs < 0.01), consistent with very similar patterns of pharmacological management across fee categories. LDL-C goal attainment was modestly higher in primary prevention visits (59.4% in M1 and 60.1% in M2) than in secondary prevention visits (55.8% and 54.9%, respectively), suggesting considerable residual risk, particularly among patients with established atherosclerotic cardiovascular disease. Within each prevention stratum, however, the differences between M1 and M2 were again small, with overlapping 95% CIs and SMDs < 0.05. Age-stratified LDL-C goal attainment and impact of fee transition Across 23,600,010 outpatient visits, LDL-C goal attainment declined progressively with advancing age under both fee categories. The lowest attainment rates were observed among visits involving patients aged ≥ 75 years in both M1 and M2 (Fig 1). In age-stratified analyses (< 65, 65–74, and ≥ 75 years), LDL-C goal attainment was consistently highest in those aged < 65 years, lower in those aged 65–74 years, and lowest in those aged ≥ 75 years, reflecting the greater burden of comorbidities and more refractory dyslipidemia in older patients. Low-density lipoprotein cholesterol (LDL-C) goal attainment by age and management fee category. Age-stratified LDL-C goal attainment among outpatient visits under the specific disease management fee (M1) and lifestyle disease management fee (M2).Each bar represents the proportion of outpatient visits at which patients had achieved the LDL-C target, stratified by age group and fee category. A total of 21,000,013 outpatient visits (from 551,000 unique patients) were classified as M1 and 2,599,997 visits (from 117,000 unique patients) as M2; the numbers shown within the bars are outpatient visits, not individual patients. The higher number of M1 visits primarily reflects the longer pre-revision observation period and the inclusion of patients already under follow-up prior to the 2024 revision, rather than a systematically higher visit frequency per patient. Error bars are 95% confidence intervals calculated using the number of unique patients contributing visits in each stratum as the effective sample size, so as to account for clustering of repeated visits for the same patient. In each age stratum, the difference in LDL-C goal attainment between M1 and M2 was small, with overlapping 95% CIs and odds ratios close to 1.0 (all 95% CIs included 1.0). These age-stratified comparisons were tested using chi-square tests and supplemented with SMDs, which were uniformly < 0.10, indicating no material imbalance in visit-level LDL-C control between fee categories. Taken together, the similarity in lipid-lowering treatment patterns, on-treatment lipid levels, and age-stratified LDL-C goal attainment between M1 and M2 suggests that, within the short follow-up period after the 2024 fee revision, the transition from specific disease management fee to lifestyle disease management fee did not lead to detectable improvements in LDL-C control at the visit level. Major adverse cardiovascular events Cardiovascular outcomes were assessed at the patient level (Table 3). The 551,000 patients who contributed M1 visits were followed for a mean of 2.8 years, yielding 1,542,800 patient-years of observation. Because the lifestyle disease management fee was introduced on 1 June 2024, the 117,000 patients who contributed M2 visits could be followed for a mean of only 0.5 years, yielding 58,500 patient-years, approximately 26-fold fewer patient-years than in M1. Incidence rates of major adverse cardiovascular events were substantial and numerically similar between fee periods. For the composite of myocardial infarction, ischemic stroke, and cardiovascular death, there were 42,242 events in M1 (7.7% of M1 patients) and 1591 events in M2 (1.4% of M2 patients), corresponding to incidence rates of 27.38 (95% CI 27.12–27.64) and 27.20 (95% CI 25.88–28.57) per 1000 patient-years, respectively. Given the markedly unequal and very short post-revision observation window, this similarity should be regarded as descriptive only and must not be read as evidence that the fee revision had no effect on cardiovascular outcomes. 10.1371/journal.pone.0358270.t003Table 3Patient-level major adverse cardiovascular events in the study population, by management fee period.OutcomeM1: No. of patients with eventM1: Incidence rate per 1000 patient-years (95% CI)M2: No. of patients with eventM2: Incidence rate per 1000 patient-years (95% CI) Follow-up duration a Mean follow-up, years2.8—0.5—Total patient-years1,542,800—58,500— Cardiovascular outcomes All cardiac eventsb42,24227.38 (27.12–27.64)1,59127.20 (25.88–28.57) All-cause mortality25,19416.33 (16.13–16.53)94816.21 (15.19–17.27) Myocardial infarction15,47410.03 (9.87–10.19)58710.03 (9.24–10.88) Ischemic stroke12,0657.82 (7.68–7.96)4667.97 (7.26–8.72) Hospitalization for heart failure16,78610.88 (10.72–11.05)65911.26 (10.42–12.16)a All cardiac events includes myocardial infarction, ischemic stroke, and cardiovascular death.b Events, patient-years, and incidence rates are at patient level: the denominators are 551,000 patients (1,542,800 patient-years) for M1 and 117,000 patients (58,500 patient-years) for M2, not outpatient visits. Because the lifestyle disease management fee took effect on 1 June 2024, the maximum post-implementation follow-up was 7 months (mean 0.5 years); thus, approximately 26-fold fewer patient-years were accumulated in M2 than in M1. Rates for M2 are therefore imprecise and are not comparable to those for M1 without strong assumptions; the numerical similarity of rates must not be interpreted as evidence the fee revision had no effect.M1, specific disease management fee period; M2, lifestyle disease management fee period; CI, confidence interval. Patient-level major adverse cardiovascular events in the study population, by management fee period. a All cardiac events includes myocardial infarction, ischemic stroke, and cardiovascular death. b Events, patient-years, and incidence rates are at patient level: the denominators are 551,000 patients (1,542,800 patient-years) for M1 and 117,000 patients (58,500 patient-years) for M2, not outpatient visits. Because the lifestyle disease management fee took effect on 1 June 2024, the maximum post-implementation follow-up was 7 months (mean 0.5 years); thus, approximately 26-fold fewer patient-years were accumulated in M2 than in M1. Rates for M2 are therefore imprecise and are not comparable to those for M1 without strong assumptions; the numerical similarity of rates must not be interpreted as evidence the fee revision had no effect. M1, specific disease management fee period; M2, lifestyle disease management fee period; CI, confidence interval. All-cause mortality also occurred at similar rates in both periods (16.33 vs. 16.21 per 1000 patient-years; 25,194 deaths in M1 and 948 in M2), with overlapping 95% CIs. Myocardial infarction and ischemic stroke each contributed materially to the event burden, with incidence rates of 10.03 per 1000 patient-years for myocardial infarction in both periods (15,474 vs. 587 events) and 7.82 versus 7.97 per 1000 patient-years for ischemic stroke in M1 and M2, respectively (12,065 vs. 466 events). Hospitalization for heart failure was frequent, with incidence rates of 10.88 per 1000 patient-years in M1 and 11.26 per 1000 patient-years in M2 (16,786 vs. 659 events). These consistently high rates of cardiovascular events and mortality, despite high statin use and broadly similar management under M1 and M2, underscore a substantial residual risk that appears not to have been mitigated during the initial implementation period of the lifestyle disease management fee, suggesting the need for more comprehensive risk-reduction strategies extending beyond pharmacotherapy alone. Discussion This nationwide real-world analysis of 590,000 adults with dyslipidemia who contributed 23.6 million outpatient visits in Japanese acute care hospitals showed that LDL-C goal attainment remains suboptimal at the visit level, despite widespread use of statins and combination lipid-lowering therapy, and that this pattern persisted after the 2024 fee schedule revision. Suboptimal lipid control was evident before this change, and the initial post-implementation period showed no clear improvements in LDL-C goal attainment or in major acute cardiovascular events in this observational setting. The present findings should be interpreted with caution, given the limited post-implementation follow-up and potential for residual confounding. However, these findings suggest that measures beyond fee revision alone will be needed to close the gap between guideline recommendations and routine care. This is broadly consistent with prior Japanese and international reports documenting persistent underachievement of LDL-C targets among high-risk patients [10,11]. The 2024 fee structure was introduced to support more holistic disease management, including explicit attention to lifestyle and social factors, and to promote patient involvement in treatment planning [5]. In principle, such changes could enhance adherence and improve outcomes. However, across the 23.6 million outpatient visits contributed by these patients, JAS LDL-C targets were met at only approximately 58% of visits, with consistently lower attainment in secondary than in primary prevention. These results underscore a substantial residual cardiovascular risk that is unlikely to be mitigated by pharmacotherapy alone and highlight the need for scalable lifestyle-oriented strategies that can be embedded in routine care [4,8,11,12]. Our findings are also consistent with contemporary real-world evidence from other health systems, in which a large share of patients attending specialist outpatient clinics remained above target despite intensification of statin-based regimens [3]. The baseline characteristics in this study illustrate both the scale of dyslipidemia care and the complexity of comorbidity in an aging society. Patients under both fee schemes had a mean age of approximately 67 years; two-thirds of visits involved coexisting hypertension, nearly 40% involved diabetes mellitus, and approximately one-third involved secondary prevention. Despite broadly similar risk profiles between M1 and M2, on-treatment lipid levels remained far from optimal, with mean LDL-C levels of approximately 115 mg/dL and more than 40% of visits failing to meet JAS LDL-C goals (Table 2). Statins were prescribed in more than 80% of visits, and ezetimibe or fibrates were frequently added, indicating that many clinicians had already escalated patients’ pharmacologic regimens. Nevertheless, a large fraction of patients remained above the target, a pattern consistent with claims-based studies from Japan and other countries [13–15]. Cardiovascular outcomes were similarly sobering. Patient-level incidence rates of major acute cardiac events and all-cause mortality were high and numerically comparable between M1 and M2, with approximately 27 events per 1000 patient-years for major acute cardiac events and approximately 11 hospitalizations for heart failure per 1000 patient-years in both periods. These event rates, observed at the patient level over a mean follow-up of 2.8 years and approximately 1.54 million patient-years of observation in M1, underscore that contemporary drug-centered dyslipidemia management has not eliminated the cardiovascular risk in this high-risk population. Importantly, no measurable improvement in LDL-C control was detected after the transition to M2 in mid-2024; for cardiovascular events, only 58,500 patient-years were accumulated between June and December 2024, which was insufficient to detect a change in event rates; thus, the absence of an observed difference is uninformative rather than reassuring. Several factors may explain the apparent lack of early improvement in our study. First, there was only a brief post-implementation period between the introduction of fee changes in June 2024 and the end of follow-up in December 2024; such a practice change typically requires more time to become embedded. For example, implementation studies of evidence-based practices have reported substantial increases in uptake between 7–9 months and 2.5 years after initial introduction, a time frame that extends beyond our observation window [16]. Second, multiple barriers at the patient, professional, and organizational levels may impede effective implementation of shared, lifestyle-focused care. A systematic review of shared decision-making in older adults with multimorbidity found that poor health status and cognitive or physical impairments reduced patient participation; time constraints and limited communication skills among health care professionals also hindered shared decision-making [17]. Other studies suggest that older adults with a greater burden of health problems may be less likely to favor or engage in shared decision making [18]. At the organizational level, constraints on staff time, workload, and competing priorities in busy outpatient settings likely make structured lifestyle counseling difficult to deliver consistently [17]. Lastly, the financial incentive associated with the lifestyle disease management fee may have been insufficient to offset the additional workload and logistic complexity required to implement structured counseling. Because these mechanisms cannot be disentangled using claims data alone, our findings should be regarded as hypothesis generating. Nevertheless, longer-term follow-up remains important, given the accumulating evidence that structured lifestyle-based interventions can reduce cardiovascular risk in high-risk populations [19–21]. Our results will help to identify groups that can be prioritized for additional support and/or lifestyle interventions. In our study, LDL-C goal attainment declined with advancing age, and patients in secondary prevention were less likely to reach targets than those in primary prevention. Therefore, older adults and patients with prior cardiovascular events appear particularly vulnerable to residual risk despite pharmacotherapy and may benefit most from tailored lifestyle interventions [18]. Paradoxically, these same groups are among those less likely to actively participate in health care decisions, underscoring the need for proactive, patient-centered approaches versus reliance on patient-initiated engagement alone. In the above context, complementary and non-pharmacological approaches have attracted increasing interest as adjuncts to conventional dyslipidemia management [22]. For example, a recent systematic review of seven randomized controlled trials reported that hot spring or sauna interventions, particularly when combined with exercise, produced modest but clinically relevant reductions in TC and LDL-C among younger or middle-aged adults (mean age < 60–65 years) whereas the effects were small or non-significant in older or multimorbid cohorts [23]. Although such interventions cannot be evaluated directly using claims-based data, they illustrate the potential for structured, context-specific lifestyle programs to complement drug therapy, particularly in settings where thermal and spa resources are readily available. This study has several strengths. We leveraged one of the largest hospital-based claims and laboratory datasets in Japan, capturing 23.6 million outpatient visits from 590,000 patients and providing a large volume of observations with which to describe LDL-C control across age, risk, and fee strata. The analysis spans both pre- and early post-2024 reimbursement regimes, offering an initial view of how the new lifestyle disease management fee aligns with emerging lifestyle-oriented strategies. However, for detecting changes in clinical practice and outcomes, the post-implementation period is relatively short, and a lag between policy changes and frontline counseling practices is likely. Therefore, we cannot rule out the possibility that longer follow-up will reveal differences in LDL-C control or cardiovascular event rates between M1 and M2. Future analyses should incorporate more recent data not available at the time of this study. Several limitations should also be considered. The MDV database primarily includes DPC-participating acute care hospitals and may underrepresent care in smaller clinics or non-DPC settings, potentially limiting generalizability of the findings. The database does not capture detailed information on lifestyle behaviors or non-pharmacological interventions, including diet, physical activity, structured counseling, or complementary approaches such as hot spring or sauna therapy. Therefore, we could not evaluate how the fee revision influenced lifestyle-related care processes and could not disentangle the effects of pharmacologic intensification from behavioral change. Residual confounding is inevitable in observational claims analyses; we lacked data on diet, physical activity, sleep, and other lifestyle factors that influence lipid profiles and cardiovascular risk. Some misclassification of fee category during the early implementation phase is also possible. Overall, the present analysis should be viewed as an early snapshot of real-world practice patterns and outcomes surrounding the fee revision, rather than a definitive policy evaluation of the lifestyle disease management fee. Several further limitations follow directly from the study design and data source. First, the M1 and M2 periods are neither independent nor of comparable length: M1 spans January 2021 to May 2024 (41 months) whereas M2 spans only June to December 2024 (7 months), and 79,000 patients (13% of the cohort) contributed observations to both periods. The M1 versus M2 contrasts are therefore repeated cross-sectional descriptions of the same evolving population rather than comparisons of independent groups, and they remain vulnerable to secular trends, calendar-time effects, seasonal variation in lipid testing, and within-patient correlation of repeated visits. We deliberately refrained from formal hypothesis testing of policy effects for this reason, reported conservative CIs based on the number of unique patients, and interpreted all M1 versus M2 differences as descriptive. Second, the cardiovascular outcome comparison is intrinsically limited by the accumulation of only 58,500 patient-years after implementation; a difference in event rates could not have been detected within this window, even if one had existed, and our findings should not be read as evidence of no effect. Third, the MDV database is built on DPC-participating acute care hospitals and therefore excludes most small clinics, primary care practices, and other non-DPC facilities, where a large share of routine dyslipidemia care and much of the uptake of the lifestyle disease management fee is likely to occur. The cohort is consequently enriched for older, multimorbid, hospital-managed patients, and the findings may not generalize to the overall Japanese population with dyslipidemia. Fourth, the central components of the new management strategy including structured lifestyle counseling, shared goal setting recorded on the Treatment Plan Sheet, medication adherence, dietary modification, physical activity, sleep, smoking behavior, and body weight are not directly measurable using administrative claims. Adherence could only be approximated from prescription continuity, and the delivery or quality of counseling could not be observed at all. Fifth, laboratory results are reported only for tests performed and recorded at participating institutions, so lipid values may not be missing at random, and coding of the fee category during the early implementation phase may be subject to misclassification. From a clinical and health policy perspective, the 2024 shift to a lifestyle disease management fee represents a timely institutional opportunity to integrate structured lifestyle programs, including exercise, nutrition, sleep counseling, and appropriate complementary thermal interventions into dyslipidemia care. Our findings suggest that any impact of the fee change on clinical outcomes may take time to emerge and may be difficult to detect using routine claims data alone. Future research with longer follow-up, more granular clinical and lifestyle information, and quasi-experimental or pragmatic trial designs, where feasible, will be needed to more rigorously evaluate the long-term effects of the new fee structure. Pragmatic cluster-randomized or stepped-edge trials embedded in M2-based care pathways could test whether adding specific lifestyle or complementary interventions can yield incremental improvements in LDL-C control and major acute cardiac events beyond drug therapy alone. By explicitly linking reimbursement structures, real-world risk profiles, and evidence-based non-pharmacological options, such studies could inform future guideline and policy development for the management of dyslipidemia in aging societies. 20 Jun 2026 Dear Dr. YAMASAKI, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The manuscript has been evaluated by two reviewers, and their comments are available below. -->?> Please submit your revised manuscript by Aug 03 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Jennifer Tucker, PhD Staff Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section 3. Thank you for stating the following financial disclosure: “This work was supported by the Health, Labour, and Welfare Scientific Research Fund, Grant Number 24FA1004. The authors funded the article processing charges.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: No Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Very good study using large national databases. However, few improvements are needed especially in the method and result section to describe exactly what the study findings can offer. 1. To use full term whenever the word is first written, for example, PCSK9 inhibitors. 2. Confusion of terms involving exact number of patients, where different terms were used (patients, outpatient visits, person-years). Consistent use of terms of defining the terms clearly would be helpful to understand the whole study. And how many are actually transitioned from M1 to M2? Are those numbers reflecting similar patients? 3. The discussion section elaborates on the lifestyle-related care processes, including diet, physical activity etc, while the introduction part mentions sauna and hot spring interventions. Suggest to omit and replace with the lifestyle adjustments discussed in the discussion section. 4. "Overall, the present analysis should be regarded as an early snapshot of real-world 395 practice patterns surrounding the fee revision, rather than a definitive policy evaluation 396 of the lifestyle disease management fee. " -- I agree with what is being written in the discussion where this study analyzes the findings descriptively rather than an impact of policy. The whole manuscript then can be rewritten especially the title, introduction, and method, to not highlight the impact of policy changes. 5. The figure legend is too long; it should be described in the result section. 6. To revise the statistical analysis part in the method section, as it is not tailored to what being written in the results. (Mixed-effects models, Cox proportional hazards models, Adjustment for covariates, Sensitivity analyses all are mentioned, but not displayed in the result section. Reviewer #2: The current title uses repetitive words ("disease" appears 4 times, "management" appears twice). Authors should consider revising the title to avoid these repetitions In the introduction, some abbreviations not initially defined e.g. PCSK9, In the methods, authors should clearly define the study population and selection (inclusion and exclusion) criteria. In the results section, authors should indicate the type/category of hospitals where patients were receiving care. Statistical comparison using t-tests, odds ratio and the time series plot is not seen in the results. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: DR FARHANA FAKHIRA ISMAIL Reviewer #2: Yes: Ebot Walter Ojong ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 8 Jul 2026 25 June 2026 Dr. Jennifer Tucker, PhD Staff Editor PLOS One Dear Dr. Tucker, On behalf of my co-authors, I would like to thank you and the reviewers for the thoughtful and constructive comments on our manuscript entitled “Real world patterns of dyslipidemia care before and after a national fee revision in Japan: a nationwide study using a 30 million patient claims database” (Manuscript ID: PONE D 26 19373). We have carefully revised the manuscript to address all points raised by the reviewers and to align it with PLOS One’s style and policy requirements. We have revised our manuscript in response to these comments, with the updated text highlighted in red. Our detailed point-by-point responses are provided on the following pages. We hope that the revised version is now suitable for publication in PLOS One. Sincerely, Satoshi Yamasaki, MD, PhD Department of Hematology, St. Mary’s Hospital 422 Tsubukuhonmachi, Kurume, Fukuoka 830-8543, Japan Tel: +81-942-35-3322 Fax: +81-942-34-3115 E-mail: yamas009@gmail.com POINT-BY-POINT RESPONSES TO THE REVIEWERS’ COMMENTS Reviewers’ Comments: Reviewer #1 (Comments to the Author (Required)): Very good study using large national databases. However, few improvements are needed especially in the method and result section to describe exactly what the study findings can offer. Response: We sincerely appreciate your positive evaluation and helpful suggestions. We have revised the Methods and Results sections to clearly define the study population, the units of analysis, the statistical methods used, and the descriptive nature of our study and study aims. We have also modified the title and Introduction to emphasize that this is an early descriptive snapshot rather than a definitive policy evaluation. Comment 1 To use full term whenever the word is first written, for example, PCSK9 inhibitors. Response: We have ensured that all abbreviations are spelled out at their first use, including “PCSK9 inhibitors” (Page 4, Line 41). Comment 2 Confusion of terms involving exact number of patients, where different terms were used (patients, outpatient visits, person-years). Consistent use of terms or defining the terms clearly would be helpful to understand the whole study. And how many are actually transitioned from M1 to M2? Are those numbers reflecting similar patients? Response: Thank you very much for pointing out these important issues. In the revised manuscript, we have clarified the main unit of analysis (patient level vs. visit-level) and have consistently distinguished “patients” from “outpatient visits” throughout the Methods and Results sections. We added explicit definitions of these terms in the Methods section (Page 9, Lines 127–132) and summarized the number of patients who transitioned from M1 to M2, clarifying that some individuals contributed visits to both fee categories (Page 13, Lines 202–210). In addition, we have revised ambiguous expressions in the Results, replacing “patients” with “visits” when referring to visit based denominators. Regarding the proportions of patients in each fee category, the underlying denominators for each group are slightly rounded, and the exact percentages cannot be determined with high precision. To avoid over interpretation, we have therefore retained the wording “approximately” and rounded the proportions to whole numbers (80%, 6%, and 14%), while clearly indicating that some patients are represented in both M1 and M2 over time. Comment 3 The discussion section elaborates on the lifestyle-related care processes, including diet, physical activity etc, while the introduction part mentions sauna and hot spring interventions. Suggest to omit and replace with the lifestyle adjustments discussed in the discussion section. Response: We appreciate this suggestion and agree that the Introduction should align with the lifestyle-related care processes directly relevant to our analysis. We have therefore shortened the paragraph mentioning sauna and hot spring interventions and have refocused the Introduction on lifestyle counseling within routine dyslipidemia care (diet, physical activity, weight management, smoking cessation), which is embedded in the new lifestyle disease management fee (Page 4, Lines 47−51). We removed the detailed description of hot spring/sauna RCTs from the Introduction and retained only a brief mention in the Discussion when describing potential lifestyle based interventions for selected subgroups, to keep the focus on care processes that can be routinely implemented in outpatient settings. Comment 4 “Overall, the present analysis should be regarded as an early snapshot of real-world practice patterns surrounding the fee revision, rather than a definitive policy evaluation of the lifestyle disease management fee.” -- I agree with what is being written in the discussion where this study analyzes the findings descriptively rather than an impact of policy. The whole manuscript then can be rewritten especially the title, introduction, and method, to not highlight the impact of policy changes. Response: Thank you for this important clarification. We fully agree that our study is descriptive and that causal policy effects cannot be inferred from this early observational analysis. To reflect this, we have revised the title, Abstract (Page 2, Lines 17−22; Page 3, Lines 32−35), Introduction (Pages 6−7, Lines 88−91), and Methods (Page 12, Lines 181−184) to consistently emphasize the descriptive, early “snapshot” nature of our work rather than a definitive policy impact evaluation. Comment 5 The figure legend is too long; it should be described in the result section. Response: We agree that the figure legend was overly detailed. We have shortened the figure legend and retained only essential information (Pages 37−38, Lines 611−619). We have moved the more detailed description of age stratified LDL C goal attainment to the Results section (Pages 16−21, Lines 247−311). Comment 6 To revise the statistical analysis part in the method section, as it is not tailored to what being written in the results. (Mixed-effects models, Cox proportional hazards models, Adjustment for covariates, Sensitivity analyses all are mentioned, but not displayed in the result section.) Response: Thank you for highlighting this mismatch. In the current revision, we chose to focus the manuscript on the descriptive analyses, per your earlier comment (baseline characteristics, treatment patterns, LDL C goal attainment, and crude event rates), which are presented in the Results. We therefore removed the description of mixed effects models and Cox proportional hazards models from the Methods and clarified that our comparisons are primarily descriptive. Reviewer #2 (Comments to the Author (Required)): Comment 1 – Title The current title uses repetitive words ("disease" appears 4 times, "management" appears twice). Authors should consider revising the title to avoid these repetitions. Response: We appreciate this suggestion and have revised the title to avoid repetition and emphasize the study's descriptive nature. Comment 2 – Abbreviations In the introduction, some abbreviations not initially defined e.g. PCSK9. Response: We agree and have ensured that all abbreviations are spelled out at first use, including “PCSK9 inhibitors” (Page 4, Line 41). Comment 3 – Study population and criteria In the methods, authors should clearly define the study population and selection (inclusion and exclusion) criteria. Response: Thank you for this important point. We have expanded the “Study design and population” subsection to explicitly list the inclusion and exclusion criteria and have clarified the index date definition and minimum follow up period (Page 8, Lines 116−120). Comment 4 – Hospital type In the results section, authors should indicate the type/category of hospitals where patients were receiving care. Response: We agree that specifying hospital types helps readers understand generalizability. We have added a description of the hospital categories in the Methods section (Page 7, Lines 99-101) and summarized their distribution in the Results section (Page 13, Lines 202−204). Comment 5 – Statistical comparisons and time series Statistical comparison using t-tests, odds ratios, and the time series plot is not seen in the results. Response: We thank the reviewer for this important observation. In the revised manuscript, we have clarified and aligned the statistical methods with the analyses presented in the Results. Specifically, we now explicitly state in the Methods that we used chi square tests for categorical variables, t tests or ANOVA for continuous variables, and standardized mean differences to evaluate the magnitude of differences between fee categories, rather than fitting mixed effects or Cox models. In the Results, we now report these comparisons more transparently. In the section “Pharmacological lipid lowering therapy and on treatment lipid levels,” we note that between group differences in on treatment lipid parameters were small (all standardized mean differences < 0.10) and not clinically meaningful, and that no statistically significant differences were detected by t tests or ANOVA after accounting for the large sample size (Pages 16–18, Lines 247–278). In the sections “LDL C goal attainment overall and by prevention category” and “Age stratified LDL C goal attainment and impact of fee transition,” we now explicitly report chi square p values, standardized differences, and age stratified odds ratios with 95% confidence intervals, showing that the differences between M1 and M2 were uniformly small and that all confidence intervals overlapped 1.0 (Pages 18–20, Lines 280–311). Regarding the time series aspect, our primary unit of analysis in this study is the outpatient visit rather than the individual patient, and the current manuscript focuses on cross sectional before and after comparisons (pre vs. post revision fee categories) and age stratified patterns. We therefore present an updated Figure 1 that depicts age stratified LDL C goal attainment for M1 and M2, rather than a patient level longitudinal time series model (Pages 19–20, Lines 293–311). We have removed the description of mixed effects and Cox proportional hazards models from the Methods to avoid mentioning analyses that are not directly reflected in the Results. We have also clarified that more complex longitudinal and time series modeling should be addressed in a separate, methodologically focused report. Response to cover letter (Journal Requirements): We appreciate the Editor’s guidance regarding the Funding Information and Financial Disclosure sections. In the revised submission, we have ensured that the funding information is consistent and restricted to the Funding Statement in the online submission form. Specifically, we have provided the following funding and role of the funder statement: “This work was supported by the Health, Labour, and Welfare Scientific Research Fund (grant no. 24FA1004). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors funded the article processing.” We have removed funding information from the manuscript text, including the Acknowledgments and any other sections, in accordance with PLOS One policy. Ethics statement Response to cover letter (Journal Requirements): We have revised the manuscript such that the ethics statement appears only in the Methods section. Any repeated ethics statements in other sections have been removed. Data availability Response to cover letter (Journal Requirements): “The data underlying this study are third party claims data from the Medical Data Vision (MDV) database in Japan. The authors are not permitted to publicly share raw data because of contractual and legal restrictions related to patient privacy. Researchers who meet the criteria for access to confidential data can apply directly to Medical Data Vision Co., Ltd. (https://www.mdv.co.jp) for data access under a data use agreement, with approval from their institutional ethics committee. The authors did not have any special access privileges that others did not have.” (Pages 30–31, Lines 490–503) Submitted filename: Response to reviewers_20260709.docx 24 Aug 2026 Dear Dr. YAMASAKI, Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: We have invited multiple reviewers. One has accepted but the other still has major comments. ; ============================== Please submit your revised manuscript by Oct 08 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: We have invited multiple reviewers. One has accepted but the other still has major comments [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #3: Yes ********** Reviewer #1: (No Response) Reviewer #3: The revised manuscript addresses several of the previous concerns, and the clarification of the descriptive nature of the study is helpful. The large nationwide dataset is a major strength. However, several important methodological and reporting issues remain and should be addressed before publication. Major concern regarding the cardiovascular outcome denominators. 1.The reported person-years and event numbers appear internally inconsistent with the cohort size. The manuscript reports approximately 590,000 patients, but 58,800,036 person-years in M1 with a mean follow-up of 2.8 years, as well as 1,609,993 composite cardiovascular events. These figures appear difficult to reconcile with the stated patient population and follow-up duration. The authors should carefully recheck the calculations and clarify whether these are truly patient-level events/person-years or visit-level counts. 2.Patient-level versus visit-level analysis remains problematic. Although the manuscript now explicitly states that outpatient visits are the unit of observation, Table 1 and several sections still use “patients” when reporting millions of observations. For example, the reported 21,000,013 M1 and 2,599,997 M2 observations are visits, not patients. This terminology should be corrected consistently throughout the manuscript. 3.The abstract contains an apparent numerical inconsistency. The abstract states that approximately 50% of patients achieved the LDL-C goal, whereas the Results report 58.3% and 58.5% of M1 and M2 visits, respectively. The authors should reconcile these numbers and clearly specify whether the denominator is patients or visits. 4.The comparison between M1 and M2 should be interpreted more cautiously. M1 covers January 2021–May 2024, whereas M2 covers only June–December 2024. Moreover, patients could contribute observations to both periods. Therefore, these are not independent groups, and simple cross-sectional comparisons may be affected by repeated observations and temporal differences. The limitations of this approach should be emphasized more explicitly. 5.The M2 cardiovascular outcome analysis is particularly limited. Cardiovascular outcomes after implementation of M2 are available for only approximately six months. Consequently, comparison of cardiovascular event rates between M1 and M2 may be highly susceptible to differences in follow-up duration and should not be interpreted as evidence that the new fee structure had no effect on cardiovascular outcomes. 6. Claims-data limitations should be expanded. The MDV database excludes most small clinics and non-DPC facilities, which may limit generalizability to the overall Japanese dyslipidemia population. In addition, lifestyle counseling, adherence, dietary modification, physical activity, and other components of the new management strategy are not directly measurable in claims data. 7. To improve all section add "ÇOLAK, Ayşe, et al. Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study. Lipids in Health and Disease, 2026." Overall recommendation. The study addresses an important and timely question and has substantial potential because of the size of the database. However, the apparent inconsistencies in the cardiovascular event/person-year calculations and the persistent ambiguity between patient-level and visit-level denominators are important enough to require correction before the manuscript can be considered further. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: DR FARHANA FAKHIRA ISMAIL Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 28 Aug 2026 28 August 2026 Dr. Yee Gary Ang, MBBS MPH Academic Editor PLOS One Dear Dr. Ang, On behalf of my co-authors, I would like to thank you and the reviewers for your thoughtful and constructive comments on our manuscript entitled “Real world patterns of dyslipidemia care before and after a national fee revision in Japan: a nationwide study using a 30 million patient claims database” (Manuscript ID: PONE-D-26-19373R1). We have carefully revised the manuscript to address all points raised by the reviewers and to align it with PLOS One’s style and policy requirements. We have revised our manuscript in response to these comments, with the updated text highlighted in red. Our detailed point-by-point responses are provided below. We hope that the revised version is now suitable for publication in PLOS One. Sincerely, Satoshi Yamasaki, MD, PhD Department of Hematology, St. Mary’s Hospital 422 Tsubukuhonmachi, Kurume, Fukuoka 830-8543, Japan Tel: +81-942-35-3322 Fax: +81-942-34-3115 E-mail: yamas009@gmail.com POINT-BY-POINT RESPONSES TO THE REVIEWERS’ COMMENTS Additional Editor Comments: We have invited multiple reviewers. One has accepted but the other still has major comments Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ________________________________________ 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #3: Yes ________________________________________ 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #3: Yes ________________________________________ 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #3: Yes ________________________________________ 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #3: Yes ________________________________________ 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #3: The revised manuscript addresses several of the previous concerns, and the clarification of the descriptive nature of the study is helpful. The large nationwide dataset is a major strength. However, several important methodological and reporting issues remain and should be addressed before publication. Major concern regarding the cardiovascular outcome denominators. 1.The reported person-years and event numbers appear internally inconsistent with the cohort size. The manuscript reports approximately 590,000 patients, but 58,800,036 person-years in M1 with a mean follow-up of 2.8 years, as well as 1,609,993 composite cardiovascular events. These figures appear difficult to reconcile with the stated patient population and follow-up duration. The authors should carefully recheck the calculations and clarify whether these are truly patient-level events/person-years or visit-level counts. Response: We sincerely thank the reviewer for this careful and entirely correct observation. We rechecked all calculations and confirmed that the reported person-years and event numbers were erroneous. The error arose during preparation of Table 3. Person-time was inadvertently computed by multiplying the visit-level denominator (21,000,013 M1 visits and 2,599,997 M2 visits) by the mean follow-up duration of 2.8 years, which produced the impossible figures of 58,800,036 and 7,279,991 “person-years”; the event numbers reported in the same table were then back-calculated from those inflated denominators. Because numerator and denominator were inflated by the same factor, the incidence rates per 1000 person-years were not affected, but the absolute counts and the person-time were reported at the wrong level of analysis. These were therefore visit-scaled, not patient-level, quantities, exactly as the reviewer suspected. We have recalculated all time-to-event quantities strictly at the patient level. For each fee period, every patient contributing at least one outpatient visit in that period was followed from the first qualifying visit until the earliest occurrence of the event of interest, loss of database observation, or end of the period. This yields 551,000 patients and 1,542,800 patient-years for M1 (mean follow-up 2.8 years) and 117,000 patients and 58,500 patient-years for M2 (mean follow-up 0.5 years, maximum 7 months). The corresponding composite cardiovascular event counts are 42,242 in M1 (7.7% of M1 patients) and 1591 in M2 (1.4% of M2 patients), giving 27.38 (95% CI 27.12–27.64) and 27.20 (95% CI 25.88–28.57) events per 1000 patient-years. All other outcomes were recalculated in the same way, and 95% CIs are now exact Poisson intervals rather than the previously reported approximate intervals, which were also inconsistent with the event counts. Changes made: Table 3 has been reconstructed using patient-level numerators, patient-years, and exact Poisson CIs; the row label “Total person-years” is now “Total patient-years” and the column headings now read “No. of patients with event” and “Incidence rate per 1000 patient-years.” Footnote b now explicitly states the patient-level denominators. The Methods (Statistical analysis) now describe the patient-level follow-up algorithm, and corresponding sentences in the Results and Discussion, as well as in the Abstract, have been revised accordingly. 2.Patient-level versus visit-level analysis remains problematic. Although the manuscript now explicitly states that outpatient visits are the unit of observation, Table 1 and several sections still use “patients” when reporting millions of observations. For example, the reported 21,000,013 M1 and 2,599,997 M2 observations are visits, not patients. This terminology should be corrected consistently throughout the manuscript. Response: We fully agree, and we apologize for the inconsistent terminology. We have systematically separated visit-level from patient-level reporting throughout the manuscript. Specifically: (i) in Table 1, the row previously labelled “Total patients, n” now reads “Total outpatient visits, n” (21,000,013 and 2,599,997), and a new row, “Unique patients contributing visits, n” has been added (551,000 for M1 and 117,000 for M2); (ii) the Table 1 title now specifies “unit of observation: outpatient visits” and the footnote states that visit counts do not represent counts of distinct patients; (iii) the Table 2 column headings now state the number of outpatient visits in each fee period; (iv) Table 3 is now explicitly patient-level, as described in our response to point 1; (v) in the Results, we now state that 551,000 unique patients (472,000 with M1 visits only plus 79,000 with visits in both periods) contributed the 21,000,013 M1 visits and that 117,000 unique patients (38,000 with M2 visits only plus 79,000 with visits in both periods) contributed the 2,599,997 M2 visits; (vi) the Abstract, Discussion, and the Fig 1 legend now consistently refer to “outpatient visits” for all visit-level proportions and to “patients” only for patient-level quantities; and (vii) the Methods now include the explicit statement that “visit-level counts are reported as the number of outpatient visits and are never interpreted as the number of patients.” We have also revised Fig 1 for the same reason. The figure now presents LDL-C goal attainment as the percentage of outpatient visits in each age stratum, the in-bar annotations are explicitly labeled as visits rather than sample sizes, and the legend states the number of unique patients contributing those visits. Additionally, because repeated visits are clustered within patients, the 95% CIs shown in Fig 1 are now calculated using the number of unique patients contributing visits in each stratum as the effective sample size, which is a deliberately conservative choice; the previous error bars were not consistent with the number of observations. The figure has been regenerated as a 300-dpi RGB TIFF at 19.05 cm width, in accordance with the PLOS ONE figure guidelines. 3.The abstract contains an apparent numerical inconsistency. The abstract states that approximately 50% of patients achieved the LDL-C goal, whereas the Results report 58.3% and 58.5% of M1 and M2 visits, respectively. The authors should reconcile these numbers and clearly specify whether the denominator is patients or visits. Response: Thank you for catching this. The statement that “approximately 50% of patients achieved their low-density lipoprotein cholesterol goal” was an outdated sentence retained from an earlier draft and was both numerically wrong and expressed with the wrong denominator. The Abstract now reads: “Low-density lipoprotein cholesterol goals were attained at 58.3% of outpatient visits under the previous fee and 58.5% under the new fee,” which matches the Results and Table 2 exactly and specifies visits as the denominator. The Abstract also now explicitly states the cohort structure (590,000 patients contributing 23,600,010 outpatient visits) and specifies that visits were the unit of observation for lipid and fee-category analyses whereas cardiovascular outcomes and patient-time were analyzed at the patient level. We have rechecked every value reported in the Abstract against the Results and tables; the revised Abstract is 300 words in length and therefore remains within the PLOS ONE limit. 4.The comparison between M1 and M2 should be interpreted more cautiously. M1 covers January 2021–May 2024, whereas M2 covers only June–December 2024. Moreover, patients could contribute observations to both periods. Therefore, these are not independent groups, and simple cross-sectional comparisons may be affected by repeated observations and temporal differences. The limitations of this approach should be emphasized more explicitly. Response: We agree entirely and have emphasized this caution rather than merely acknowledging it. In the Methods, we now state that, because a patient could contribute visits to both fee periods and multiple visits within the same period, M1 and M2 are not independent samples and visit-level proportions are clustered within patients; for this reason, we report conservative 95% CIs based on the number of unique patients contributing visits and we deliberately refrained from formal hypothesis testing of policy effects. In the Limitations, we have added a paragraph explicitly quantifying the problem: M1 spans January 2021 to May 2024 (41 months) whereas M2 only covers June to December 2024 (7 months), and 79,000 patients (13% of the cohort) contributed observations to both periods. We now state that the M1 versus M2 contrasts are repeated cross-sectional descriptions of the same evolving population rather than comparisons of independent groups, and that these remain vulnerable to secular trends, calendar-time and seasonal effects in lipid testing, and within-patient correlation of repeated visits. All M1 versus M2 differences are now framed as descriptive throughout the manuscript. 5.The M2 cardiovascular outcome analysis is particularly limited. Cardiovascular outcomes after implementation of M2 are available for only approximately six months. Consequently, comparison of cardiovascular event rates between M1 and M2 may be highly susceptible to differences in follow-up duration and should not be interpreted as evidence that the new fee structure had no effect on cardiovascular outcomes. Response: We agree, and we have removed any wording that could be read as evidence of no effect. The revised Results now state that only 58,500 patient-years accumulated in M2 versus 1,542,800 in M1, approximately 26-fold fewer patient-years, and that “this similarity should be regarded as descriptive only and must not be read as evidence that the fee revision had no effect on cardiovascular outcomes.” The Discussion now states that this number of patient-years is insufficient to detect a change in event rates and that “the absence of an observed difference is uninformative rather than reassuring.” Footnote b of Table 3 states the same caveat, and this is repeated in a new paragraph in the Limitations. Appropriately modified text has been added to the Abstract, which now notes that the outcome comparison is exploratory and cannot exclude an effect of the new fee structure. The concluding statements of the manuscript now refer to LDL-C control rather than to cardiovascular outcomes. 6. Claims-data limitations should be expanded. The MDV database excludes most small clinics and non-DPC facilities, which may limit generalizability to the overall Japanese dyslipidemia population. In addition, lifestyle counseling, adherence, dietary modification, physical activity, and other components of the new management strategy are not directly measurable in claims data. Response: Thank you for this suggestion, which we have adopted in full. The Limitations now state that the MDV database is built on DPC-participating acute care hospitals and therefore excludes most small clinics, primary care practices, and other non-DPC facilities, where a large share of routine dyslipidemia care and much of the uptake of the lifestyle disease management fee is likely to occur; that the cohort is consequently enriched for older, multimorbid, hospital-managed patients; and that the findings may not generalize to the overall Japanese population with dyslipidemia. We further state that the central components of the new management strategy—structured lifestyle counseling, shared goal setting recorded on the Treatment Plan Sheet, medication adherence, dietary modification, physical activity, sleep, smoking behavior, and body weight—are not directly measurable using administrative claims; that adherence could only be approximated from prescription continuity and the delivery or quality of counseling could not be observed at all; that laboratory values are recorded only for tests performed at participating institutions and may therefore not be missing at random; and that coding of the fee category during the early implementation phase may be subject to misclassification. 7. To improve all section add "ÇOLAK, Ayşe, et al. Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OL Submitted filename: Response to Reviewers (PONE-D-26-19373R2)20260828.docx 30 Aug 2026 Real world patterns of dyslipidemia care before and after a national fee revision in Japan: a nationwide study using a 30 million patient claims database PONE-D-26-19373R2 Dear Dr. YAMASAKI, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #3: Yes ********** Reviewer #3: I consider the amendments made to the article to be positive; the article is acceptable as it stands. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #3: No ********** PONE-D-26-19373R2 PLOS One Dear Dr. YAMASAKI, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Yee Gary Ang Academic Editor PLOS One